BidaskClub Lowers Medidata Solutions (NASDAQ:MDSO) to Hold
MDSO has been the topic of a number of other research reports. Wells Fargo & Co reiterated a hold rating on shares of Medidata Solutions in a research report on Thursday, June 13th. SunTrust Banks lifted their target price on Medidata Solutions from $85.00 to $92.25 and gave the company a hold rating in a research report on Thursday, June 13th. JPMorgan Chase & Co. upgraded Medidata Solutions from an underweight rating to a neutral rating in a research report on Wednesday, June 12th. Dougherty & Co lowered Medidata Solutions from a buy rating to a neutral rating in a research note on Wednesday, May 1st. Finally, William Blair lowered Medidata Solutions from an outperform rating to a market perform rating in a research note on Wednesday, June 12th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the stock. Medidata Solutions has a consensus rating of Hold and a consensus price target of $84.27.
Shares of NASDAQ MDSO opened at $91.61 on Tuesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.56 and a current ratio of 2.56. Medidata Solutions has a 52 week low of $60.10 and a 52 week high of $98.60. The stock has a market capitalization of $5.72 billion, a P/E ratio of 95.43, a PEG ratio of 6.05 and a beta of 1.23. The stock’s fifty day moving average is $91.14 and its 200 day moving average is $84.91.
In other news, Director Robert Taylor sold 3,294 shares of Medidata Solutions stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $90.88, for a total transaction of $299,358.72. Following the sale, the director now directly owns 41,757 shares of the company’s stock, valued at $3,794,876.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.70% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Quadrant Capital Group LLC lifted its stake in shares of Medidata Solutions by 126.8% in the first quarter. Quadrant Capital Group LLC now owns 592 shares of the company’s stock worth $40,000 after acquiring an additional 331 shares during the period. Flagship Harbor Advisors LLC lifted its stake in Medidata Solutions by 58.3% in the second quarter. Flagship Harbor Advisors LLC now owns 475 shares of the company’s stock valued at $42,000 after buying an additional 175 shares during the period. FTB Advisors Inc. lifted its stake in Medidata Solutions by 212.4% in the second quarter. FTB Advisors Inc. now owns 934 shares of the company’s stock valued at $84,000 after buying an additional 635 shares during the period. Tower Research Capital LLC TRC lifted its stake in Medidata Solutions by 102.0% in the second quarter. Tower Research Capital LLC TRC now owns 1,697 shares of the company’s stock valued at $153,000 after buying an additional 857 shares during the period. Finally, Meeder Asset Management Inc. acquired a new position in Medidata Solutions in the second quarter valued at approximately $185,000. 91.15% of the stock is currently owned by institutional investors.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.